Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000075.xml
Download PDF
Semin Respir Crit Care Med 2007; 28(4): 418-429
DOI: 10.1055/s-2007-985613
DOI: 10.1055/s-2007-985613
The Spectrum of Scleroderma Lung Disease
Further Information
Publication History
Publication Date:
03 September 2007 (online)
ABSTRACT
Pulmonary disease is the most common cause of death in patients with systemic sclerosis. This article discusses the variety of ways the lung is affected in systemic sclerosis. These include pulmonary hypertension, interstitial lung disease and other restrictive disorders, obstructive disease, pleural disease, lung cancer, and aspiration. For each manifestation we outline the current knowledge of etiology, risk factors, diagnosis, treatment, and prognosis. We also discuss the current state of lung transplantation in this population.
KEYWORDS
Scleroderma - systemic sclerosis - interstitial lung disease - pulmonary arterial hypertension
REFERENCES
- 1 Silver R M. Scleroderma: clinical problems: the lungs. Rheum Dis Clin North Am. 1996; 22 825-840
- 2 Steen V D, Medsger Jr T A. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum. 2000; 43 2437-2444
- 3 Clements PJ, Furst DE Systemic Sclerosis. Baltimore: Williams and Wilkins 1996
MissingFormLabel
- 4 Williams M H, Das C, Handler C E et al.. Systemic sclerosis associated pulmonary hypertension: improved survival in the current era. Heart. 2006; 92 926-932
- 5 McLaughlin V V, Presberg K W, Doyle R L et al.. Prognosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest. 2004; 126 78S-92S
- 6 Girgis R E, Mathai S C, Krishnan J A, Wigley F M, Hassoun P M. Long-term outcome of bosentan treatment in idiopathic pulmonary arterial hypertension and pulmonary arterial hypertension associated with the scleroderma spectrum of diseases. J Heart Lung Transplant. 2005; 24 1626-1631
- 7 Kawut S M, Taichman D B, Archer-Chicko C L, Palevsky H I, Kimmel S E. Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis. Chest. 2003; 123 344-350
- 8 MacGregor A J, Canavan R, Knight C et al.. Pulmonary hypertension in systemic sclerosis: risk factors for progression and consequences for survival. Rheumatology (Oxford). 2001; 40 453-459
- 9 Tan R T, Kuzo R, Goodman L R, Siegel R, Haasler G B, Presberg K W. Utility of CT scan evaluation for predicting pulmonary hypertension in patients with parenchymal lung disease. Medical College of Wisconsin Lung Transplant Group. Chest. 1998; 113 1250-1256
- 10 Barst R J, McGoon M, Torbicki A et al.. Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol. 2004; 43 40S-47S
- 11 Arcasoy S M, Christie J D, Ferrari V A et al.. Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease. Am J Respir Crit Care Med. 2003; 167 735-740
- 12 Alkotob M L, Soltani P, Sheatt M A et al.. Reduced exercise capacity and stress-induced pulmonary hypertension in patients with scleroderma. Chest. 2006; 130 176-181
- 13 Battle R W, Davitt M A, Cooper S M et al.. Prevalence of pulmonary hypertension in limited and diffuse scleroderma. Chest. 1996; 110 1515-1519
- 14 Koh E T, Lee P, Gladman D D, Abu-Shakra M. Pulmonary hypertension in systemic sclerosis: an analysis of 17 patients. Br J Rheumatol. 1996; 35 989-993
- 15 MacGregor A J, Canavan R, Knight C et al.. Pulmonary hypertension in systemic sclerosis: risk factors for progression and consequences for survival. Rheumatology (Oxford). 2001; 40 453-459
- 16 Morelli S, Ferrante L, Sgreccia A et al.. Pulmonary hypertension is associated with impaired exercise performance in patients with systemic sclerosis. Scand J Rheumatol. 2000; 29 236-242
- 17 Mukerjee D, St George D, Coleiro B et al.. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis. 2003; 62 1088-1093
- 18 Murata I, Kihara H, Shinohara S, Ito K. Echocardiographic evaluation of pulmonary arterial hypertension in patients with progressive systemic sclerosis and related syndromes. Jpn Circ J. 1992; 56 983-991
- 19 Sacks D G, Okano Y, Steen V D, Curtiss E, Shapiro L S, Medsger Jr T A. Isolated pulmonary hypertension in systemic sclerosis with diffuse cutaneous involvement: association with serum anti-U3RNP antibody. J Rheumatol. 1996; 23 639-642
- 20 Scorza R, Caronni M, Bazzi S et al.. Post-menopause is the main risk factor for developing isolated pulmonary hypertension in systemic sclerosis. Ann N Y Acad Sci. 2002; 966 238-246
- 21 Stupi A M, Steen V D, Owens G R, Barnes E L, Rodnan G P, Medsger Jr T A. Pulmonary hypertension in the CREST syndrome variant of systemic sclerosis. Arthritis Rheum. 1986; 29 515-524
- 22 Ungerer R G, Tashkin D P, Furst D et al.. Prevalence and clinical correlates of pulmonary arterial hypertension in progressive systemic sclerosis. Am J Med. 1983; 75 65-74
- 23 Hesselstrand R, Ekman R, Eskilsson J et al.. Screening for pulmonary hypertension in systemic sclerosis: the longitudinal development of tricuspid gradient in 227 patients, 1992-2001. Rheumatology (Oxford). 2005; 44 366-371
- 24 Wigley F M, Lima J A, Mayes M, McLain D, Chapin J L, Ward-Able C. The prevalence of undiagnosed pulmonary arterial hypertension in subjects with connective tissue disease at the secondary health care level of community-based rheumatologists (the UNCOVER study). Arthritis Rheum. 2005; 52 2125-2132
- 25 Yamane K, Ihn H, Asano Y et al.. Clinical and laboratory features of scleroderma patients with pulmonary hypertension. Rheumatology (Oxford). 2000; 39 1269-1271
- 26 Pope J E, Lee P, Baron M et al.. Prevalence of elevated pulmonary arterial pressures measured by echocardiography in a multicenter study of patients with systemic sclerosis. J Rheumatol. 2005; 32 1273-1278
- 27 Chang B, Shachna L, White B, Wigley F M, Wise R A. Natural history of mild-moderate pulmonary hypertension and the risk factors for severe pulmonary hypertension in scleroderma. J Rheumatol. 2006; 33 269-274
- 28 Schachna L, Wigley F M, Chang B, White B, Wise R A, Gelber A C. Age and risk of pulmonary arterial hypertension in scleroderma. Chest. 2003; 124 2098-2104
- 29 Steen V, Medsger Jr T A. Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Arthritis Rheum. 2003; 48 516-522
- 30 Chang B, Wigley F M, White B, Wise R A. Scleroderma patients with combined pulmonary hypertension and interstitial lung disease. J Rheumatol. 2003; 30 2398-2405
- 31 Williams M H, Handler C E, Akram R et al.. Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension. Eur Heart J. 2006; 27 1485-1494
- 32 Assous N, Allanore Y, Batteux F et al.. Prevalence of antiphospholipid antibodies in systemic sclerosis and association with primitive pulmonary arterial hypertension and endothelial injury. Clin Exp Rheumatol. 2005; 23 199-204
- 33 Fisher M R, Mathai S C, Champion H C et al.. Clinical differences between idiopathic and scleroderma-related pulmonary hypertension. Arthritis Rheum. 2006; 54 3043-3050
- 34 Strange C, Bolster M, Mazur J, Taylor M, Gossage J R, Silver R. Hemodynamic effects of epoprostenol in patients with systemic sclerosis and pulmonary hypertension. Chest. 2000; 118 1077-1082
- 35 Badesch D B, Abman S H, Ahearn G S et al.. Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest. 2004; 126 35S-62S
- 36 Rich S, Seidlitz M, Dodin E et al.. The short-term effects of digoxin in patients with right ventricular dysfunction from pulmonary hypertension. Chest. 1998; 114 787-792
- 37 Rich S, Kaufmann E, Levy P S. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med. 1992; 327 76-81
- 38 Fuster V, Steele P M, Edwards W D, Gersh B J, McGoon M D, Frye R L. Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation. 1984; 70 580-587
- 39 Hoeper M M. Pulmonary hypertension in collagen vascular disease. Eur Respir J. 2002; 19 571-576
- 40 Sanchez O, Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary hypertension secondary to connective tissue diseases. Thorax. 1999; 54 273-277
- 41 Alpert M A, Pressly T A, Mukerji V et al.. Acute and long-term effects of nifedipine on pulmonary and systemic hemodynamics in patients with pulmonary hypertension associated with diffuse systemic sclerosis, the CREST syndrome and mixed connective tissue disease. Am J Cardiol. 1991; 68 1687-1691
- 42 Glikson M, Pollack A, Dresner-Feigin R, Galun E, Rubinow A. Nifedipine and prazosin in the management of pulmonary hypertension in CREST syndrome. Chest. 1990; 98 759-761
- 43 O'Brien J T, Hill J A, Pepine C J. Sustained benefit of verapamil in pulmonary hypertension with progressive systemic sclerosis. Am Heart J. 1985; 109 380-382
- 44 Sfikakis P P, Kyriakidis M K, Vergos C et al.. Cardiopulmonary hemodynamics in systemic sclerosis and response to nifedipine and captopril. Am J Med. 1991; 90 541-546
- 45 Shinohara S, Murata I, Yamada H et al.. Combined effects of diltiazem and oxygen in pulmonary hypertension of mixed connective tissue disease. J Rheumatol. 1994; 21 1763-1765
- 46 Hachulla E, Coghlan J G. A new era in the management of pulmonary arterial hypertension related to scleroderma: endothelin receptor antagonism. Ann Rheum Dis. 2004; 63 1009-1014
- 47 Galiè N, Manes A, Farahani K V et al.. Pulmonary arterial hypertension associated to connective tissue diseases. Lupus. 2005; 14 713-717
- 48 Braun-Moscovici Y, Menahem Nahir A, Balbir-Gurman A. Endothelin and pulmonary arterial hypertension. Semin Arthritis Rheum. 2004; 34 442-453
- 49 Humbert M, Morrell N W, Archer S L et al.. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol. 2004; 43 13S-24S
- 50 Badesch D B, Tapson V F, McGoon M D et al.. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease: a randomized, controlled trial. Ann Intern Med. 2000; 132 425-434
- 51 Oudiz R J, Schilz R J, Barst R J et al.. Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease. Chest. 2004; 126 420-427
- 52 Olschewski H, Simonneau G, Galiè N et al.. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med. 2002; 347 322-329
- 53 Galiè N, Ghofrani H A, Torbicki A et al.. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2005; 353 2148-2157
- 54 Rubin L J, Badesch D B, Barst R J et al.. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002; 346 896-903
- 55 Joglekar A, Tsai F S, McCloskey D A, Wilson J E, Seibold J R, Riley D J. Bosentan in pulmonary arterial hypertension secondary to scleroderma. J Rheumatol. 2006; 33 61-68
- 56 Diot E, Boissinot E, Asquier E et al.. Relationship between abnormalities on high-resolution CT and pulmonary function in systemic sclerosis. Chest. 1998; 114 1623-1629
- 57 Wells A U, Rubens M B, du Bois R M, Hansell D M. Serial CT in fibrosing alveolitis: prognostic significance of the initial pattern. AJR Am J Roentgenol. 1993; 161 1159-1165
- 58 Ostojic P, Damjanov N. Different clinical features in patients with limited and diffuse cutaneous systemic sclerosis. Clin Rheumatol. 2006; 25 453-457
- 59 Morelli S, Barbieri C, Sgreccia A et al.. Relationship between cutaneous and pulmonary involvement in systemic sclerosis. J Rheumatol. 1997; 24 81-85
- 60 Shimizu Y, Tsukagoshi H, Nemoto T, Honma M, Nojima Y, Mori M. Recurrent bronchiolitis obliterans organizing pneumonia in a patient with limited cutaneous systemic sclerosis. Rheumatol Int. 2002; 22 216-218
- 61 Bridges A J, Hsu K C, Dias-Arias A A, Chechani V J. Bronchiolitis obliterans organizing pneumonia and scleroderma. J Rheumatol. 1992; 19 1136-1140
- 62 Cox D, Conant E, Earle L et al.. Sarcoidosis in systemic sclerosis: report of 7 cases. J Rheumatol. 1995; 22 881-885
- 63 De Bandt M, Perrot S, Masson C, Meyer O. Systemic sclerosis and sarcoidosis, a report of 5 cases. Br J Rheumatol. 1997; 36 117-119
- 64 Kim D S, Yoo B, Lee J S et al.. The major histopathologic pattern of pulmonary fibrosis in scleroderma is nonspecific interstitial pneumonia. Sarcoidosis Vasc Diffuse Lung Dis. 2002; 19 121-127
- 65 Bouros D, Wells A U, Nicholson A G et al.. Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med. 2002; 165 1581-1586
- 66 Fujita J, Yoshinouchi T, Ohtsuki Y et al.. Non-specific interstitial pneumonia as pulmonary involvement of systemic sclerosis. Ann Rheum Dis. 2001; 60 281-283
- 67 Desai S R, Veeraraghavan S, Hansell D M et al.. CT features of lung disease in patients with systemic sclerosis: comparison with idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia. Radiology. 2004; 232 560-567
- 68 Terriff B A, Kwan S Y, Chan-Yeung M M, Muller N L. Fibrosing alveolitis: chest radiography and CT as predictors of clinical and functional impairment at follow-up in 26 patients. Radiology. 1992; 184 445-449
- 69 Warrick J H, Bhalla M, Schabel S I, Silver R M. High-resolution computed tomography in early scleroderma lung disease. J Rheumatol. 1991; 18 1520-1528
- 70 Ooi G C, Mok M Y, Tsang K W et al.. Interstitial lung disease in systemic sclerosis. Acta Radiol. 2003; 44 258-264
- 71 Silver R M, Metcalf J F, Stanley J H, LeRoy E C. Interstitial lung disease in scleroderma: analysis by bronchoalveolar lavage. Arthritis Rheum. 1984; 27 1254-1262
- 72 Remy-Jardin M, Remy J, Wallaert B, Bataille D, Hatron P Y. Pulmonary involvement in progressive systemic sclerosis: sequential evaluation with CT, pulmonary function tests and bronchoalveolar lavage. Radiology. 1993; 188 499-506
- 73 De Santis M, Bosello S, La Torre G et al.. Functional, radiological and biological markers of alveolitis and infections of the lower respiratory tract in patients with systemic sclerosis. Respir Res. 2005; 6 96
- 74 Clements P J, Goldin J G, Kleerup E C et al.. Regional differences in bronchoalveolar lavage and thoracic high-resolution computed tomography results in dyspneic patients with systemic sclerosis. Arthritis Rheum. 2004; 50 1909-1917
- 75 Silver R, Goldin J G, Strange C et al.. Alveolitis determination in scleroderma lung disease: CT or bronchoalveolar lavage (BAL)? [abstract]. Am J Respir Crit Care Med. 2004; 169 A227
- 76 Guttadauria M, Ellman H, Emmanuel G, Kaplan D, Diamond H. Pulmonary function in scleroderma. Arthritis Rheum. 1977; 20 1071-1079
- 77 Spagnolatti L, Zoia M C, Volpini E et al.. Pulmonary function in patients with systemic sclerosis. Monaldi Arch Chest Dis. 1997; 52 4-8
- 78 Jacobsen S, Halberg P, Ullman S et al.. A longitudinal study of pulmonary function in Danish patients with systemic sclerosis. Clin Rheumatol. 1997; 16 384-390
- 79 Plastiras S C, Karadimitrakis S P, Ziakas P D, Vlachoyiannopoulos P G, Moutsopoulos H M, Tzelepis G E. Scleroderma lung: initial forced vital capacity as predictor of pulmonary function decline. Arthritis Rheum. 2006; 55 598-602
- 80 Steen V D, Conte C, Owens G R, Medsger Jr T A. Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum. 1994; 37 1283-1289
- 81 Steen V D, Graham G, Conte C, Owens G, Medsger Jr T A. Isolated diffusing capacity reduction in systemic sclerosis. Arthritis Rheum. 1992; 35 765-770
- 82 Diot E, Giraudeau B, Diot P et al.. Is anti-topoisomerase I a serum marker of pulmonary involvement in systemic sclerosis?. Chest. 1999; 116 715-720
- 83 Maricq H R, LeRoy E C, D'Angelo W A et al.. Diagnostic potential of in vivo capillary microscopy in scleroderma and related disorders. Arthritis Rheum. 1980; 23 183-189
- 84 Bredemeier M, Xavier R M, Capobianco K G et al.. Nailfold capillary microscopy can suggest pulmonary disease activity in systemic sclerosis. J Rheumatol. 2004; 31 286-294
- 85 White B, Moore W C, Wigley F M, Xiao H Q, Wise R A. Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann Intern Med. 2000; 132 947-954
- 86 Akesson A, Scheja A, Lundin A, Wollheim F A. Improved pulmonary function in systemic sclerosis after treatment with cyclophosphamide. Arthritis Rheum. 1994; 37 729-735
- 87 Silver R M, Warrick J H, Kinsella M B, Staudt L S, Baumann M H, Strange C. Cyclophosphamide and low-dose prednisone therapy in patients with systemic sclerosis (scleroderma) with interstitial lung disease. J Rheumatol. 1993; 20 838-844
- 88 Steen V D, Lanz Jr J K, Conte C, Owens G R, Medsger Jr T A. Therapy for severe interstitial lung disease in systemic sclerosis. Arthritis Rheum. 1994; 37 1290-1296
- 89 Pakas I, Ioannidis J P, Malagari K, Skopouli F N, Moutsopoulos H M, Vlachoyiannopoulos P G. Cyclophosphamide with low- or high-dose prednisolone for systemic sclerosis lung disease. J Rheumatol. 2002; 29 298-304
- 90 Griffiths B, Miles S, Moss H, Robertson R, Veale D, Emery P. Systemic sclerosis and interstitial lung disease: a pilot study using pulse intravenous methylprednisolone and cyclophosphamide to assess the effect of high resolution computed tomography scan and lung function. J Rheumatol. 2002; 29 2371-2378
- 91 Airo P, Danieli E, Parrinello G et al.. Intravenous cyclophosphamide therapy for systemic sclerosis: a single-center experience and review of the literature with pooled analysis of lung function test results. Clin ExpRheumatol. 2004; 22 573-578
- 92 Apras S, Ertenli I, Ozbalkan Z et al.. Effects of oral cyclophosphamide and prednisolone therapy on the endothelial functions and clinical findings in patients with early diffuse systemic sclerosis. Arthritis Rheum. 2003; 48 2256-2261
- 93 Davas E M, Peppas C, Maragou M, Alvanou E, Hondros D, Dantis P C. Intravenous cyclophosphamide pulse therapy for the treatment of lung disease associated with scleroderma. Clin Rheumatol. 1999; 18 455-461
- 94 Tashkin D P, Elashoff R, Clements P J et al.. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med. 2006; 354 2655-2666
- 95 Hoyles R K, Ellis R W, Wellsbury J et al.. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum. 2006; 54 3962-3970
- 96 Dheda K, Lalloo U G, Cassim B, Mody G M. Experience with azathioprine in systemic sclerosis associated with interstitial lung disease. Clin Rheumatol. 2004; 23(4) 306-309
- 97 Liossis S N, Bounas A, Andonopoulos A P. Mycophenolate mofetil as first-line treatment improves clinically evident early scleroderma lung disease. Rheumatology (Oxford). 2006; 45 1005-1008
- 98 Swigris J J, Olson A L, Fischer A et al.. Mycophenolate mofetil is safe, well tolerated, and preserves lung function in patients with connective tissue disease-related interstitial lung disease. Chest. 2006; 130 30-36
- 99 Olsen N J, King L E, Park J H. Muscle abnormalities in scleroderma. Rheum Dis Clin North Am. 1996; 22 783-796
- 100 Clements P J, Furst D E, Campion D S et al.. Muscle disease in progressive systemic sclerosis: diagnostic and therapeutic consideration. Arthritis Rheum. 1978; 21 62-71
- 101 Abramson M J, Barnett A J, Littlejohn G O, Smith M M, Hall S. Lung function abnormalities and decline of spirometry in scleroderma: an overrated danger?. Postgrad Med J. 1991; 67 632-637
- 102 Vitali C, Viegi G, Tassoni S et al.. Lung function abnormalities in different connective tissue diseases. Clin Rheumatol. 1986; 5 181-188
- 103 Blom-Bulow B, Jonson B, Brauer K. Lung function in progressive systemic sclerosis is dominated by poorly compliant lungs and stiff airways. Eur J Respir Dis. 1985; 66 1-8
- 104 Owens G R, Fino G J, Herbert D L et al.. Pulmonary function in progressive systemic sclerosis: comparison of CREST syndrome variant with diffuse scleroderma. Chest. 1983; 84 546-550
- 105 Bjerke R D, Tashkin D P, Clements P J, Chopra S K, Gong Jr H, Bein M. Small airways in progressive systemic sclerosis (PSS). Am J Med. 1979; 66 201-219
- 106 Boehler A, Vogt P, Speich R et al.. Bronchiolitis obliterans in a patient with localized scleroderma treated with D-penicillamine. Eur Respir J. 1996; 9 1317-1319
- 107 Thompson A E, Pope J E. A study of the frequency of pericardial and pleural effusions in scleroderma. Br J Rheumatol. 1998; 37 1320-1323
- 108 Taormina V J, Miller W T, Gefter W B, Epstein D M. Progressive systemic sclerosis subgroups: variable pulmonary features. AJR Am J Roentgenol. 1981; 137 277-285
- 109 Zeuner M, Muller-Ladner U, Mohr V D, Lang B. Spontaneous pneumothorax in a patient with systemic sclerosis. Clin Rheumatol. 1996; 15 211-213
- 110 Suresh K, Radha R, Ananthasubramaniam G, Chandrasekaran A N. An unusual presentation of progressive systemic sclerosis. J Assoc Physicians India. 1994; 42 163-164
- 111 Ng S C, Tan W C. Bilateral spontaneous pneumothorax in systemic sclerosis-report of two cases. J Rheumatol. 1990; 17 689-691
- 112 Lang B, Ortlieb H, Meske S, Hauke G, Peter H H. Progressive systemic sclerosis presenting with spontaneous pneumothorax. J Rheumatol. 1989; 16 254-256
- 113 Daniels C E, Jett J R. Does interstitial lung disease predispose to lung cancer?. Curr Opin Pulm Med. 2005; 11 431-437
- 114 Hazleman B. Incidence of neoplasms in patients with rheumatoid arthritis exposed to different treatment regimens. Am J Med. 1985; 78 39-43
- 115 Hill C L, Nguyen A M, Roder D, Roberts-Thomson P. Risk of cancer in patients with scleroderma: a population based cohort study. Ann Rheum Dis. 2003; 62 728-731
- 116 Rosenthal A K, McLaughlin J K, Linet M S, Persson I. Scleroderma and malignancy: an epidemiological study. Ann Rheum Dis. 1993; 52 531-533
- 117 Yang Y, Fujita J, Tokuda M, Bandoh S, Ishida T. Lung cancer associated with several connective tissue disease: with a review of literature. Rheumatol Int. 2001; 21 106-111
- 118 Roumm A D, Medsger Jr T A. Cancer and systemic sclerosis: an epidemiologic study. Arthritis Rheum. 1985; 28 1336-1340
- 119 Winkelmann R K, Flach D B, Unni K K. Lung cancer and scleroderma. Arch Dermatol Res. 1988; 280 S15-S18
- 120 Chatterjee S, Dombi G W, Severson R K, Mayes M D. Risk of malignancy in scleroderma: a population-based cohort study. Arthritis Rheum. 2005; 52 2415-2424
- 121 Bhalla M, Silver R M, Shepard J A, McLoud T C. Chest CT in patients with scleroderma: prevalence of asymptomatic esophageal dilatation and mediastinal lymphadenopathy. AJR Am J Roentgenol. 1993; 161 269-272
- 122 Marie I, Dominique S, Levesque H et al.. Esophageal involvement and pulmonary manifestations in systemic sclerosis. Arthritis Rheum. 2001; 45 346-354
- 123 Lock G, Pfeifer M, Straub R H et al.. Association of esophageal dysfunction and pulmonary function impairment in systemic sclerosis. Am J Gastroenterol. 1998; 93 341-345
- 124 Ing A J. Interstitial lung disease and gastroesophageal reflux. Am J Med. 2001; 111 41S-44S
- 125 Troshinsky M B, Kane G C, Varga J et al.. Pulmonary function and gastroesophageal reflux in systemic sclerosis. Ann Intern Med. 1994; 121 6-10
- 126 D'Ovidio F, Singer L G, Hadjiliadis D et al.. Prevalence of gastroesophageal reflux in end-stage lung disease candidates for lung transplant. Ann Thorac Surg. 2005; 80 1254-1260
- 127 Rosas V, Conte J V, Yang S C et al.. Lung transplantation and systemic sclerosis. Ann Transplant. 2000; 5 38-43
- 128 Massad M G, Powell C R, Kpodonu J et al.. Outcomes of lung transplantation in patients with scleroderma. World J Surg. 2005; 29 1510-1515
- 129 Nash R A, McSweeney P A, Nelson J L et al.. Allogeneic marrow transplantation in patients with severe systemic sclerosis: resolution of dermal fibrosis. Arthritis Rheum. 2006; 54 1982-1986
Kristin B HighlandM.D. M.S.C.R.
Medical University of South Carolina
96 Jonathan Lucas St., Ste. 812 CSB, Charleston, SC 29425
Email: highlakb@musc.edu